Literature DB >> 1911845

Purification of the proteinase from group B streptococci that inactivates human C5a.

J F Bohnsack1, X N Zhou, P A Williams, P P Cleary, C J Parker, H R Hill.   

Abstract

We previously reported that group B streptococci (GBS) possess a cell-associated activity that inactivates the chemotactic activity generated in zymosan-activated serum by cleaving a specific site within the carboxy termini of C5a and C5adesarg. This inactivates the major chemoattractants for neutrophils that are generated when serum complement is activated. We now report the isolation of the enzyme responsible for the proteolytic cleavage of C5a. Treatment of GBS with mutanolysin, an endo-N-acetyl muramidase, released activity from GBS which destroyed the functional activity of C5a. The soluble activity was purified to homogeneity by hydroxyapatite, ion-exchange and gel-filtration chromatography. Analysis by SDS-PAGE showed that the enzyme (GBS C5a-ase) has an Mr of approx. 120,000. The GBS C5a-ase appears to be a serine esterase on the basis of its sensitivity to di-isopropyl fluorophosphate. This enzyme is distinct from the C5a-cleaving enzyme produced by group A streptococci, since the two bacterial products migrate differently on SDS-PAGE, and lack antigenic cross reactivity. This enzyme may play a role in the pathogenesis of group B streptococcal disease through its ability to rapidly inactivate the potent neutrophil agonist, C5a, at sites of infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911845     DOI: 10.1016/0167-4838(91)90129-n

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

1.  Streptococcus thermophilus cell wall-anchored proteinase: release, purification, and biochemical and genetic characterization.

Authors:  M D Fernandez-Espla; P Garault; V Monnet; F Rul
Journal:  Appl Environ Microbiol       Date:  2000-11       Impact factor: 4.792

2.  Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes.

Authors:  Irina V Koroleva; Androulla Efstratiou; Alexander N Suvorov
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

3.  Camelysin is a novel surface metalloproteinase from Bacillus cereus.

Authors:  Gregor Grass; Angelika Schierhorn; Eduard Sorkau; Helmut Müller; Peter Rücknagel; Dietrich H Nies; Beate Fricke
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

4.  Conservation of the C5a peptidase genes in group A and B streptococci.

Authors:  I Chmouryguina; A Suvorov; P Ferrieri; P P Cleary
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

5.  A novel immunogenic spore coat-associated protein in Bacillus anthracis: characterization via proteomics approaches and a vector-based vaccine system.

Authors:  Yu-Tsueng Liu; Shwu-Bin Lin; Cheng-Po Huang; Chun-Ming Huang
Journal:  Protein Expr Purif       Date:  2007-09-14       Impact factor: 1.650

6.  Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.

Authors:  J F Bohnsack; J K Chang; H R Hill
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

7.  Similarity between the group B and A streptococcal C5a peptidase genes.

Authors:  P P Cleary; J Handley; A N Suvorov; A Podbielski; P Ferrieri
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

8.  A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen.

Authors:  Theresa O Harris; Daniel W Shelver; John F Bohnsack; Craig E Rubens
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

9.  Ubiquitous occurrence of virR and scpA genes in group A streptococci.

Authors:  A Podbielski
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

10.  The surface protein Srr-1 of Streptococcus agalactiae binds human keratin 4 and promotes adherence to epithelial HEp-2 cells.

Authors:  Ulrike Samen; Bernhard J Eikmanns; Dieter J Reinscheid; Frédéric Borges
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.